<tei xml:space="preserve">
    <teiHeader>
        <fileDesc xml:id="_0"/>
    </teiHeader>
    <text xml:lang="en">
        <listBibl>

        REFERENCES<lb/> 
        <bibl><label>1</label>. Weidinger S, Beck LA, Bieber T, Kabashima K,<lb/> Irvine AD. Atopic dermatitis. Nat Rev Dis Primers.<lb/> 2018;4(1):1. doi:10.1038/s41572-018-0001-z<lb/> </bibl>
        <bibl><label>2</label>. Langan SM, Irvine AD, Weidinger S. Atopic<lb/> dermatitis. Lancet. 2020;396(10247):345-360.<lb/> doi:10.1016/S0140-6736(20)31286-1<lb/> </bibl>
        <bibl><label>3</label>. Howell MD, Kuo FI, Smith PA. Targeting the<lb/> Janus kinase family in autoimmune skin diseases.<lb/> Front Immunol. 2019;10:2342. doi:10.3389/<lb/> fimmu.2019.02342<lb/> </bibl>
        <bibl><label>4</label>. He H, Guttman-Yassky E. JAK inhibitors for<lb/> atopic dermatitis: an update. Am J Clin Dermatol.<lb/> 2019;20(2):181-192. doi:10.1007/<lb/> s40257-018-0413-2<lb/> </bibl>
        <bibl><label>5</label>. Simpson EL, Bieber T, Guttman-Yassky E, et al;<lb/> SOLO 1 and SOLO 2 Investigators. Two phase 3 trials<lb/> of dupilumab versus placebo in atopic dermatitis.<lb/> N Engl J Med. 2016;375(24):2335-2348. doi:10.<lb/> 1056/NEJMoa1610020<lb/> </bibl>
        <bibl><label>6</label>. Parmentier JM, Voss J, Graff C, et al. In vitro and<lb/> in vivo characterization of the JAK1 selectivity of<lb/> upadacitinib (ABT-494). BMC Rheumatol. 2018;2:23.<lb/> doi:10.1186/s41927-018-0031-x<lb/> </bibl>
        <bibl><label>7</label>. Guttman-Yassky E, Thaçi D, Pangan AL, et al.<lb/> Upadacitinib in adults with moderate to severe<lb/> atopic dermatitis: 16-week results from a<lb/> randomized, placebo-controlled trial. J Allergy Clin<lb/> Immunol. 2020;145(3):877-884. doi:10.1016/<lb/> j.jaci.2019.11.025<lb/> </bibl>
        <bibl><label>8</label>. Guttman-Yassky E, Teixeira HD, Simpson EL,<lb/> et al. Once-daily upadacitinib versus placebo in<lb/> adolescents and adults with moderate-to-severe<lb/> atopic dermatitis (Measure Up 1 and Measure Up 2):<lb/> results from two replicate double-blind,<lb/> randomised controlled phase 3 trials. Lancet. 2021;<lb/> 397(10290):2151-2168. doi:10.1016/<lb/> S0140-6736(21)00588-2<lb/> </bibl>
        <bibl><label>9</label>. Reich K, Teixeira HD, de Bruin-Weller M, et al.<lb/> Safety and efficacy of upadacitinib in combination<lb/> with topical corticosteroids in adolescents and<lb/> adults with moderate-to-severe atopic dermatitis<lb/> (AD Up): results from a randomised, double-blind,<lb/> placebo-controlled, phase 3 trial. Lancet. 2021;397<lb/> (10290):2169-2181. doi:10.1016/<lb/> S0140-6736(21)00589-4<lb/> </bibl>
        <bibl><label>10</label>. World Medical Association. World Medical<lb/> Association Declaration of Helsinki: ethical<lb/> principles for medical research involving human<lb/> subjects. JAMA. 2013;310(20):2191-2194. doi:10.<lb/> 1001/jama.2013.281053<lb/> </bibl>
        <bibl><label>11</label>. Hanifin JM, Rajka G. Diagnostic features of<lb/> atopic dermatitis. Acta Dermatovener (Stockholm).<lb/> 1980;60(92):44-47.<lb/> </bibl>
        <bibl><label>12</label>. Silverberg JI, Lei D, Yousaf M, et al. What are the<lb/> best endpoints for Eczema Area and Severity Index<lb/> and Scoring Atopic Dermatitis in clinical practice? a<lb/> prospective observational study. Br J Dermatol.<lb/> 2021;184(5):888-895. doi:10.1111/bjd.19457<lb/> </bibl>
        <bibl><label>13</label>. Schmitt J, Csötönyi F, Bauer A, Meurer M.<lb/> Determinants of treatment goals and satisfaction of<lb/> patients with atopic eczema. J Dtsch Dermatol Ges.<lb/> 2008;6(6):458-465. doi:10.1111/j.1610-0387.2007.<lb/> 06609.x<lb/> </bibl>
        <bibl><label>14</label>. Silverberg JI, Kantor RW, Dalal P, et al. A<lb/> comprehensive conceptual model of the<lb/> experience of chronic itch in adults. Am J Clin<lb/> Dermatol. 2018;19(5):759-769. doi:10.1007/s40257-<lb/>018-0381-6<lb/> </bibl>
        <bibl><label>15</label>. Augustin M, Langenbruch A, Blome C, et al.<lb/> Characterizing treatment-related patient needs in<lb/> atopic eczema: insights for personalized goal<lb/> orientation. J Eur Acad Dermatol Venereol. 2020;34<lb/> (1):142-152. doi:10.1111/jdv.15919<lb/> </bibl>
        <bibl><label>16</label>. Leung DY, Guttman-Yassky E. Deciphering the<lb/> complexities of atopic dermatitis: shifting<lb/> paradigms in treatment approaches. J Allergy Clin<lb/> Immunol. 2014;134(4):769-779. doi:10.1016/j.jaci.<lb/> 2014.08.008<lb/> </bibl>
        <bibl><label>17</label>. Silverberg JI, Simpson EL, Thyssen JP, et al.<lb/> Efficacy and safety of abrocitinib in patients with<lb/> moderate-to-severe atopic dermatitis:<lb/> a randomized clinical trial. JAMA Dermatol.<lb/> 2020;156(8):863-873. doi:10.1001/<lb/> jamadermatol.2020.1406<lb/> </bibl>
        <bibl><label>18</label>. Simpson EL, Sinclair R, Forman S, et al. Efficacy<lb/> and safety of abrocitinib in adults and adolescents<lb/> with moderate-to-severe atopic dermatitis (JADE<lb/> MONO-1): a multicentre, double-blind, randomised,<lb/> placebo-controlled, phase 3 trial. Lancet. 2020;396<lb/> (10246):255-266. doi:10.1016/<lb/> S0140-6736(20)30732-7<lb/> </bibl>
        <bibl><label>19</label>. Simpson EL, Lacour JP, Spelman L, et al.<lb/> Baricitinib in patients with moderate-to-severe<lb/> atopic dermatitis and inadequate response to<lb/> topical corticosteroids: results from two<lb/> randomized monotherapy phase III trials. Br J<lb/> Dermatol. 2020;183(2):242-255. doi:10.1111/<lb/> bjd.18898<lb/> </bibl>
        <bibl><label>20</label>. Eichenfield LF, Tom WL, Berger TG, et al.<lb/> Guidelines of care for the management of atopic<lb/> dermatitis, section 2: management and treatment<lb/> of atopic dermatitis with topical therapies. J Am<lb/> Acad Dermatol. 2014;71(1):116-132. doi:10.1016/j.<lb/> jaad.2014.03.023</bibl>
        </listBibl>
    </text>
</tei>

